Education
About Us
Working with TipRanks
Follow Us
Skye Bioscience, Inc. (SKYE)
NASDAQ:SKYE
SKYE Stock Chart & Stats
$1.00
-$0.06(-1.95%)
At close: 4:00 PM EST
$1.00
-$0.06(-1.95%)
Day’s Range― - ―
52-Week Range$0.68 - $5.75
Previous CloseN/A
Volume18.00K
Average Volume (3M)492.37K
Market Cap
$32.06M
Enterprise Value$13.94M
Total Cash (Recent Filing)$35.31M
Total Debt (Recent Filing)$321.85K
Price to Earnings (P/E)―
Beta3.08
Next Earnings
Mar 19, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding32,057,460
10 Day Avg. Volume503,696
30 Day Avg. Volume492,366
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-3.85
Enterprise Value/Market Cap0.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.28
Forecast
1Y Price Target
$11.25Price Target Upside1025.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Combination EfficacyPhase 2a results indicated nimacimab produced an incremental, clinically meaningful weight-loss benefit and improved body composition when combined with semaglutide, supporting its role as a safe adjunct to deepen and extend GLP-1 therapy effects.
Delivery TechnologyCollaborations around ENHANZE and higher-concentration formulations could enable subcutaneous delivery of higher nimacimab doses with standard auto-injectors, simplifying clinical development and future commercialization compared with pump-based approaches.
Safety Enabling Dose EscalationClean safety and tolerability observed in trials provide room to escalate dosing and justify planned dose-ranging studies aimed at improving monotherapy and combination efficacy.
Bears Say
Baseline Imbalances And Data ReliabilityImbalances in patient baseline characteristics could have influenced trial outcomes, complicating efficacy interpretation and raising development and regulatory risk.
Monotherapy Efficacy ShortfallMonotherapy performance was disappointing at tested dose levels, showing minimal activity and indicating that current exposure may be insufficient for standalone efficacy.
PK/PD Exposure UncertaintyUncertainty exists whether the updated population pharmacokinetic/pharmacodynamic analysis will confirm that higher-dose delivery reliably reaches target exposure across a broad patient population.
Skye Bioscience News
SKYE FAQ
What was Skye Bioscience, Inc.’s price range in the past 12 months?
Skye Bioscience, Inc. lowest stock price was $0.68 and its highest was $5.75 in the past 12 months.
What is Skye Bioscience, Inc.’s market cap?
Skye Bioscience, Inc.’s market cap is $32.06M.
When is Skye Bioscience, Inc.’s upcoming earnings report date?
Skye Bioscience, Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 59 days.
How were Skye Bioscience, Inc.’s earnings last quarter?
Skye Bioscience, Inc. released its earnings results on Nov 10, 2025. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.314 by -$0.006.
Is Skye Bioscience, Inc. overvalued?
According to Wall Street analysts Skye Bioscience, Inc.’s price is currently Undervalued.
Does Skye Bioscience, Inc. pay dividends?
Skye Bioscience, Inc. does not currently pay dividends.
What is Skye Bioscience, Inc.’s EPS estimate?
Skye Bioscience, Inc.’s EPS estimate is -0.3.
How many shares outstanding does Skye Bioscience, Inc. have?
Skye Bioscience, Inc. has 32,057,460 shares outstanding.
What happened to Skye Bioscience, Inc.’s price movement after its last earnings report?
Skye Bioscience, Inc. reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.314. Following the earnings report the stock price went up 2.817%.
Which hedge fund is a major shareholder of Skye Bioscience, Inc.?
Currently, no hedge funds are holding shares in SKYE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Skye Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.25 (1025.00% Upside)
$11.25 (1025.00% Upside)
Blogger Sentiment
Bullish
SKYE Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 60.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.96%
12-Months-Change
Fundamentals
Return on Equity
-94.31%
Trailing 12-Months
Asset Growth
-49.32%
Trailing 12-Months
Company Description
Skye Bioscience, Inc.
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
SKYE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong financial health and promising Phase 2a study results highlighting the potential of Nimazumab in combination with semaglutide. However, increased R&D expenses, a larger net loss, concerns about monotherapy efficacy, and limited study enrollment were notable challenges.View all SKYE earnings summariesSKYE Stock 12 Month Forecast
Average Price Target
$11.25
▲(1025.00% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Outlook Therapeutics
―
Bioxcel Therapeutics
―
Inmune Bio
―
Lantern Pharma
―
Ownership Overview
Currently, No data available
---